These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Resveratrol as an adjunct therapy in cyclophosphamide-treated MCF-7 cells and breast tumor explants.
    Author: Singh N, Nigam M, Ranjan V, Zaidi D, Garg VK, Sharma S, Chaturvedi R, Shankar R, Kumar S, Sharma R, Mitra K, Balapure AK, Rath SK.
    Journal: Cancer Sci; 2011 May; 102(5):1059-67. PubMed ID: 21276137.
    Abstract:
    Cyclophosphamide (CPA) has efficacy as a breast cancer therapy. However, toxicity to CPA limits its clinical applications. Hence there is a need to develop compounds that may be combined with it to improve the efficacy and overcome toxicity. We showed previously that Resveratrol (RES), a chemopreventive agent, increased the growth inhibitory effect of CPA-treated MCF-7 cells. Here we have explored the molecular basis of 5 mM CPA and 50 μM RES as a combination on cell-cycle progression, apoptosis and oxidative stress in MCF-7 breast cancer cells. Efficacy of the combination was also evaluated in a serum-free tumor explant culture model. The combination elicited enhanced anti-proliferative action coupled with differential expression of cell-cycle, apoptosis and stress factors. Furthermore, co-treatment superiority in histologically validated ER positive breast cancer explants suggests that this combination may be a worthy future clinical anti-neoplastic regimen.
    [Abstract] [Full Text] [Related] [New Search]